Form 4: Myriad Genetics SVP Margaret Ancona Reports Stock Transactions

Margaret Ancona, SVP and Chief of Staff at Myriad Genetics, reports the acquisition and disposal of company stock, including restricted stock units and shares withheld for tax obligations.

Summary

• Margaret Ancona, SVP and Chief of Staff at Myriad Genetics, filed a Form 4 detailing changes in beneficial ownership.
• On March 14, 2024, Ancona acquired 35,178 shares of common stock through time-based restricted stock units granted under the company's 2017 Equity Incentive Plan.
• These restricted stock units vest in three equal annual installments starting on the first anniversary of the grant date.
• On March 15, 2024, 1,585 shares were disposed of at a price of $21.16 to cover tax withholding obligations related to the vesting of restricted stock units.
• Following these transactions, Ancona directly owns 91,634 shares of Myriad Genetics common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment as the filing reflects routine stock transactions related to equity compensation and tax obligations. No significant positive or negative implications are apparent.

Positives

• The acquisition of restricted stock units indicates confidence in the company's future performance.

Negatives

• The disposal of shares to cover tax obligations, while routine, slightly reduces Ancona's holdings.

Risks

• The value of the restricted stock units is subject to the market price of Myriad Genetics' common stock.

Future Outlook

The restricted stock units vest in three equal annual installments beginning on the first anniversary of the grant date, suggesting continued alignment of Ancona's interests with the company's performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the stock transactions of company insiders. This filing is typical for executives receiving equity compensation.

Comparison to Industry Standards

• Equity compensation is a common practice among publicly traded companies to incentivize executives and align their interests with shareholders.
• The vesting schedule of the restricted stock units (three equal annual installments) is a standard vesting arrangement.
• Comparable companies such as Exact Sciences and Invitae also utilize equity compensation as part of their executive compensation packages.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are part of routine executive compensation.

Key Dates